CHEK2 antibody (AA 481-531)

Catalog No. ABIN1724714

The Mouse Monoclonal anti-CHEK2 antibody has been validated for WB, ELISA, IHC and ICC. It is suitable to detect CHEK2 in samples from Human. There are 3+ publications available.

Quick Overview for CHEK2 antibody (AA 481-531) (ABIN1724714)

Target: CHEK2 (Checkpoint Kinase 2 (CHEK2))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CHEK2 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunocytochemistry (ICC)

Clone: 1C12B8

Product Details anti-CHEK2 Antibody

Binding Specificity: AA 481-531

Purpose: CHK2 Antibody

Purification: Ascitic fluid

Immunogen: Purified recombinant fragment of human CHK2 (aa481-531) expressed in E. Coli.

Isotype: IgG2b

Application Details

Application Notes:

ELISA: 1/10000

ICC: 1/200 - 1/1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

References for anti-CHEK2 antibody (ABIN1724714)

Cybulski, Masojc, Oszutowska, Jaworowska, Grodzki, Waloszczyk, Serwatowski, Pankowski, Huzarski, Byrski, Górski, Jakubowska, Debniak, Wokolorczyk, Gronwald, Tarnowska, Serrano-Fernández, Lubinski et al.: "Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. ..." in: Carcinogenesis, Vol. 29, Issue 4, pp. 762-5, (2008) (PubMed).

Antoni, Sodha, Collins, Garrett: "CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?" in: Nature reviews. Cancer, Vol. 7, Issue 12, pp. 925-36, (2007) (PubMed).

Bell, Kim, Godwin, Schiripo, Harris, Haserlat, Wahrer, Haiman, Daly, Niendorf, Smith, Sgroi, Garber, Olopade, Le Marchand, Henderson, Altshuler, Haber, Freedman: "Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts." in: International journal of cancer. Journal international du cancer, Vol. 121, Issue 12, pp. 2661-7, (2007) (PubMed).

Target Details for CHEK2

Target: CHEK2 (Checkpoint Kinase 2 (CHEK2))

Alternative Name: CHK2

Background: CHK2: CHK2 checkpoint homolog (S. pombe). In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Three transcript variants encoding different isoforms have been found for this gene.

Molecular Weight: 61 kDa

UniProt: O96017

Pathways: p53 Signaling, Apoptosis, Cell Division Cycle